Longitudinal Cohort Study Comparing 2 Surgical Techniques in Patients With Class 3 Obesity and Type 2 Diabetes
- Conditions
- Type 2 DiabetesObesity
- Interventions
- Procedure: Roux-en-Y gastric bypassProcedure: Adjustable gastric band
- Registration Number
- NCT00688974
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
Wight loss surgery provides good glycemic control in type 2 diabetes. The technique of "Roux-en-Y gastric bypass" is more effective than the "Adjustable Gastric Band" on weight loss.
This longitudinal cohort study will compare the effectiveness of the Roux-en-Y gastric bypass and Adjustable Gastric Banding on glycemic control in type 2 diabetes and explore the responsible mechanisms.
The evaluation will be made preoperatively and 1 year later as assessed by the decline in HbA1c. An evaluation will also be carried out after a weight loss of 10% to indicate whether the observed difference is independent of weight loss.
- Detailed Description
Type 2 diabetes is a condition often associated with obesity and often difficult to control. In patients with severe obesity, surgical treatment allows a sustainable weight loss and higher than that obtained with other treatments available. In most cases, surgery also reduces significantly the comorbidities of obesity and diabetes in particular. Among the various technical options, adjustable gastric band (AGB) is the simplest and by far the most used in France.
Roux-en-Y gastric bypass (RYGB) is a more complicated intervention combining gastrointestinal malabsorption- duodeno-jejunal and gastric reduction and allows a higher weight loss. Several studies also suggest that the technique has a remarkable efficiency on glycemic control, justifying the extension of its readings/indications. No study controlled, however, has compared these two techniques.
The objective of this study is to compare the efficiency of RYGB vs AGB on glycemic control in type 2 diabetes. Although some studies have compared AGB and RYGB, none have compared their effectiveness on post prandial glucose control in patients with diabetes. It is generally recognized that the effectiveness of RYGB on diabetes is independent of the weight loss, but this has never been demonstrated.
By demonstrating the superiority of RYGB vs AGB, and identifying the responsible mechanisms, the study will expand the indications of RYGB in the treatment of type 2 diabetes. Weight loss surgery offers a unique model for the clinical study of the pathophysiology of type 2 diabetes.
Main objective:
* To compare the effectiveness of RYGB vs AGB on glucose control in obese patients with type 2 diabetes.
Secondary Objectives:
* demonstrate that the better outcome achieved with RYGB is independent of weight loss.
* Identify the mechanisms underlying the better outcome of RYGB
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
- Age between 18 and 70 years AND
- BMI > 35
- Type 2 diabetes
- Obesity for more than 5 years OR
- normoglycemia
- BMI< 30
- Secondary obesity due to an endocrinopathy
- Chronic pathology (neoplasia, cirrhosis, disease of system)
- Psychosis, alcoholic addiction or narcotics.
- Contre-indications to the anaesthesia
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Roux-en-Y gastric bypass Roux-en-Y gastric bypass Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass Adjustable gastric banding Adjustable gastric band Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
- Primary Outcome Measures
Name Time Method Glucose control 12 months HbA1c and fasting blood glucose
- Secondary Outcome Measures
Name Time Method Glycaemia, Insulinemia, Incretins during a standardized meal test at 10% of weight loss 3 months Concentration curves of glycaemia, insulinemia, incretins, and D-xylose during a standardized mixed meal test
Diabetes remission 60 months HbA1c \< 6.5% AND fasting blood glucose \< 7.0 mmol/L in absence of antidiabetic drug
Glycaemia, Insulinemia, Incretins, and D-xylose during a normalized(standardized) meal 12 months Concentration curves of glycaemia, insulinemia, incretins, and D-xylose during a standardized mixed meal test
Weight loss 60 months Body mass index
Glycaemia, insulinemia, incretins, and D-xylose during a normalized(standardized) meal 60 months Concentration curves of glycaemia, insulinemia, incretins, and D-xylose during a standardized mixed meal test
Trial Locations
- Locations (1)
Lille University Hospital
🇫🇷Lille, Nord, France
Lille University Hospital🇫🇷Lille, Nord, France